海南医学院学报2017，Vol.23Issue(16)：2203-2206,4.DOI:10.13210/j.cnki.jhmu.20170821.002
利拉鲁肽治疗对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用
Regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity
摘要
Abstract
Objective: To investigate the regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity.Methods: A total of 118 patients with newly diagnosed type 2 diabetes complicated with obesity who were treated in the hospital were collected and divided into the control group (n=59) and observation group (n=59) by random number table.Control group received metformin therapy and the observation group received liraglutide therapy.The differences in levels of glucose metabolism indexes, lipid metabolism indexes and inflammatory factors were compared between the two groups before and after 4 months of treatment.Results: Before treatment, the differences in serum levels of glucose metabolism indexes, lipid metabolism indexes and inflammatory factors were not statistically significant between the two groups (P>0.05).Four months after treatment, serum FPG, FIN, F-CP, TC, TG, IL-1β, IL-6, CRP and TNF-α levels of both groups of patients were lower than those before treatment, while HDL-C levels were higher than those before treatment, and serum FPG, FIN, F-CP, TC, TG, IL-1β, IL-6, CRP and TNF-α levels of observation group were lower than those of control group, while HDL-C level was higher than that of control group.Conclusion: Liraglutide therapy can effectively optimize the glucose lipid metabolism and reduce the microinflammatory response in patients with type 2 diabetes mellitus complicated with obesity.关键词
2型糖尿病/肥胖/利拉鲁肽/脂代谢/炎症反应Key words
Type 2 diabetes mellitus/Obesity/Liraglutide/Lipid metabolism/Inflammatory response分类
医药卫生引用本文复制引用
高冬梅,包山丹..利拉鲁肽治疗对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用[J].海南医学院学报,2017,23(16):2203-2206,4.基金项目
首都卫生发展科研专项(2016-1-2057) （2016-1-2057）
首都卫生发展科研专项(2016-2-2054) （2016-2-2054）
首都临床特色应用研究项目(Z151100004015021)This study was supported by the Capital Health Research and Development of Special (2016-1-2057) （Z151100004015021）
the Capital Health Research and Development of Special (2016-2-2054) （2016-2-2054）
the Capital Clinical Application Research Project (Z151100004015021). （Z151100004015021）
